Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026)
Olema Pharmaceuticals' (OLMA) quarterly Depreciation & Amortization (CF) came in at $119000.0 in Q1 2026, down 7.03% year-on-year from $128000.0 in Q1 2025, and down 36.36% on a QoQ basis from $187000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $119000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 7.03% year-over-year to $119000.0 in Q1 2026; TTM through Mar 2026 was $481000.0, a 11.09% increase from a year earlier, with the FY2025 full-year figure at $490000.0, up 24.68% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $119000.0, down from $187000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for OLMA reached as high as $187000.0 in Q4 2025 and fell as low as $43000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $102117.6 across 5 years, with a median of $95000.0 in 2024.
- Across the five-year window, Depreciation & Amortization (CF) jumped 833.33% in 2022 and tumbled 54.74% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $97000.0 in 2022, then fell by 9.28% to $88000.0 in 2023, then surged by 31.82% to $116000.0 in 2024, then jumped by 61.21% to $187000.0 in 2025, then sank by 36.36% to $119000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $119000.0 in Q1 2026, $187000.0 in Q4 2025, and $43000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Olema Pharmaceuticals | 1.21 Bn | 1.21 Bn | - | 119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119,000.00 |
| Mar 31, 2026 | 119,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 88,000.00 |
| Dec 31, 2023 | 88,000.00 |